Literature DB >> 1929286

Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats.

P Longuet1, V Joly, P Amirault, N Seta, C Carbon, P Yeni.   

Abstract

Amphotericin B (AMB), either alone or incorporated into small unilamellar vesicles of pure dipalmitoylphosphatidyl choline (DPPC SUV-AMB), was administered intravenously to male Sprague-Dawley rats once daily for 5 days. Either 1.5 or 3.5 mg of AMB or DPPC SUV-AMB per kg was given, since these concentrations corresponded, respectively, to the lowest nephrotoxic dose and the sublethal dose of AMB in our model. Tubular functions were evaluated daily, and AMB concentrations in plasma, urine, and tissues were measured by high-performance liquid chromatography. AMB at both doses induced tubular toxicity, hyposthenuria being the earliest symptom. DPPC SUV-AMB at 1.5 mg/kg/day was atoxic, but the tubular alterations induced by 3.5 mg of DPPC SUV-AMB per kg were similar to those observed with 3.5 mg of AMB per kg, except that the ability to concentrate urine was partly restored 72 h after the last infusion. Incorporating AMB into DPPC SUV did not influence the pharmacokinetics of the drug. Using this lipidic AMB formulation, we thus observed a beneficial effect toward limiting the renal tubular toxicity of repeated low doses of AMB but, unexpectedly, not that of high doses. These results indicate that tubular renal functions and electrolyte serum values should be closely monitored in patients treated with AMB liposomal formulations, especially high-dose regimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929286      PMCID: PMC245162          DOI: 10.1128/AAC.35.7.1303

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  NEPHROTOXIC TUBULAR DAMAGE AND CALCIUM DEPOSITION FOLLOWING AMPHOTERICIN B THERAPY.

Authors:  P T WERTLAKE; W T BUTLER; G J HILL; J P UTZ
Journal:  Am J Pathol       Date:  1963-09       Impact factor: 4.307

2.  AMPHOTERICIN B RENAL TOXICITY IN THE DOG.

Authors:  W T BUTLER; G J HILL; C F SZWED; V KNIGHT
Journal:  J Pharmacol Exp Ther       Date:  1964-01       Impact factor: 4.030

3.  On the nephrotoxicity of amphotericin B in man.

Authors:  N H BELL; V T ANDRIOLE; S M SABESIN; J P UTZ
Journal:  Am J Med       Date:  1962-07       Impact factor: 4.965

4.  The treatment of deep mycotic infections with amphotericin B1 with particular emphasis on drug toxicity.

Authors:  H W BEARD; J H RICHERT; R R TAYLOR
Journal:  Am Rev Respir Dis       Date:  1960-01

5.  Studies on glucosaminidase; N-acetyl-beta-glucosaminidase in rat kidney.

Authors:  D PUGH; D H LEABACK; P G WALKER
Journal:  Biochem J       Date:  1957-03       Impact factor: 3.857

6.  Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes.

Authors:  L Pisarik; V Joly; S Jullien; C Carbon; P Yeni
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

7.  Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.

Authors:  K M Wasan; K Vadiei; G Lopez-Berestein; D R Luke
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

8.  Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.

Authors:  V Joly; L Saint-Julien; C Carbon; P Yeni
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

9.  Pentoxifylline in amphotericin B toxicity rat model.

Authors:  K M Wasan; K Vadiei; G Lopez-Berestein; R R Verani; D R Luke
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

10.  Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  J A Gondal; R P Swartz; A Rahman
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more
  5 in total

Review 1.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Authors:  I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

4.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.

Authors:  V Joly; R Farinotti; L Saint-Julien; M Chéron; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats.

Authors:  K R Reuhl; M Vapiwala; M T Ryzlak; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.